微生物和情绪：抑郁症创新的生物标志物方法
Microbes and mood: innovative biomarker approaches in depression
影响因子:13.80000
分区:医学1区 Top / 生化与分子生物学1区 医学：研究与实验1区 细胞生物学2区
发表日期:2025 Jan
作者:
Miranda Green, Madhukar H Trivedi, Jane A Foster
摘要
尽管精神病学领域在生物标志物发现方面取得了收益，但我们改变长期结局的能力仍然不足。将个人与最佳待遇相匹配是持续的临床挑战。此外，由于对有助于临床异质性的个体差异的生物学机制的了解有限，因此部分由于对生物学机制的了解有限，因此受到了阻碍。肠道微生物组已成为从代谢性疾病到癌症等疾病的深入研究领域。这些空间中的创新导致了转化的突破，提供了新型的微生物组知觉方法，可以改善患者的结果。在这篇综述中，我们研究了转化微生物组研究的准备如何推进心理健康中的生物标志物发现，重点是抑郁。
Abstract
Although the field of psychiatry has made gains in biomarker discovery, our ability to change long-term outcomes remains inadequate. Matching individuals to the best treatment for them is a persistent clinical challenge. Moreover, the development of novel treatments has been hampered in part due to a limited understanding of the biological mechanisms underlying individual differences that contribute to clinical heterogeneity. The gut microbiome has become an area of intensive research in conditions ranging from metabolic disorders to cancer. Innovation in these spaces has led to translational breakthroughs, offering novel microbiome-informed approaches that may improve patient outcomes. In this review we examine how translational microbiome research is poised to advance biomarker discovery in mental health, with a focus on depression.